Unión Europea - español - EMA (European Medicines Agency)

intervet international bv - cepa tw928 de streptococcus equi mutante por deleción en vivo - inmunológicos para équidos - caballos - para la inmunización de caballos contra streptococcus equi para reducir los signos clínicos y la aparición de abscesos linfáticos. inicio de la inmunidad: el inicio de la inmunidad se establece como dos semanas después de la vacunación básica. duración de la inmunidad: la duración de la inmunidad es de hasta tres meses. la vacuna está destinada para uso en caballos para que un riesgo de infección por streptococcus equi ha sido claramente identificados, debido al contacto con los caballos de las áreas en donde este patógeno es conocido por estar presente, e. establos con caballos que viajan a espectáculos o competiciones en tales áreas, o establos que obtienen o tienen caballos de librea de dichas áreas.

Unión Europea - español - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; myelodysplastic syndromes; lymphoma, follicular; lymphoma, mantle-cell - inmunosupresores - multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) está indicado para el tratamiento de pacientes adultos no tratados previamente con mieloma múltiple que no son elegibles para el trasplante. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 y 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) está indicado para el tratamiento de pacientes adultos no tratados previamente con mieloma múltiple que no son elegibles para el trasplante. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 y 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Unión Europea - español - EMA (European Medicines Agency)

astrazeneca ab - osimertinib mesilate - carcinoma, pulmón no microcítico - otros agentes antineoplásicos, inhibidores de la proteína quinasa - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.

Unión Europea - español - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride hydrate - multiple myeloma; lymphoma, follicular; myelodysplastic syndromes - inmunosupresores - multiple myelomalenalidomide krka d. as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) está indicado para el tratamiento de pacientes adultos no tratados previamente con mieloma múltiple que no son elegibles para el trasplante. lenalidomide krka d. in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka d. as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. follicular lymphomalenalidomide krka d. in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

zoetis belgium sa - escherichia coli, viva atenuada, delecion en el gen aro a, tipo o78, cepa ec34195 - liofilizado para suspensiÓn - excipientes: sulfato magnesico heptahidratado, hidrogenofosfato de potasio, sacarosa, sulfato de amonio, hidrogenofosfato de disodio heptahidrato - escherichia - pollos de engorde, pollos de reposición

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

zoetis belgium sa - escherichia coli, viva atenuada, delecion en el gen aro a, tipo o78, cepa ec34195 - liofilizado para suspensiÓn - excipientes: sulfato magnesico heptahidratado, hidrogenofosfato de potasio, sacarosa, sulfato de amonio, hidrogenofosfato de disodio heptahidrato - escherichia - pollos de engorde, pollos de reposición

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

zoetis belgium sa - escherichia coli, viva atenuada, delecion en el gen aro a, tipo o78, cepa ec34195 - liofilizado para suspensiÓn - excipientes: sulfato magnesico heptahidratado, hidrogenofosfato de potasio, sacarosa, sulfato de amonio, hidrogenofosfato de disodio heptahidrato - escherichia - pollos de engorde, pollos de reposición

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

zoetis belgium sa - escherichia coli, viva atenuada, delecion en el gen aro a, tipo o78, cepa ec34195 - liofilizado para suspensiÓn - excipientes: sulfato magnesico heptahidratado, hidrogenofosfato de potasio, sacarosa, sulfato de amonio, hidrogenofosfato de disodio heptahidrato - escherichia - pollos de engorde, pollos de reposición

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

zoetis belgium sa - escherichia coli, viva atenuada, delecion en el gen aro a, tipo o78, cepa ec34195 - liofilizado para suspensiÓn - excipientes: sulfato magnesico heptahidratado, hidrogenofosfato de potasio, sacarosa, sulfato de amonio, hidrogenofosfato de disodio heptahidrato - escherichia - pollos de engorde, pollos de reposición

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

zoetis belgium sa - escherichia coli, viva atenuada, delecion en el gen aro a, tipo o78, cepa ec34195 - liofilizado para suspensiÓn - excipientes: sulfato magnesico heptahidratado, hidrogenofosfato de potasio, sacarosa, sulfato de amonio, hidrogenofosfato de disodio heptahidrato - escherichia - pollos de engorde, pollos de reposición